Insmed Announces PAH Presentations at the American Thoracic Society 2015 Meeting

Patrícia Silva, PhD avatar

by Patrícia Silva, PhD |

Share this article:

Share article via email
PAH disease

Insmed Incorporated, a biopharmaceutical company dedicated to improving the lives of patients battling rare lung diseases by developing orphan treatments recently announced that during the 2015 Annual Internation Conference of the American Thoracic Society (ATS) it will present three ARIKAYCE™ abstracts and three INS1009 abstracts. The conference will place from today until de 20th of May in Denver.

ARIKAYCE or liposomal amikacin for inhalation is a form of the antibiotic amikacin which is enclosed in nanocapsules of lipid called liposomes. This advanced pulmonary liposome technology prolongs the release of amikacin in the lungs while minimizing systemic exposure, and is in late-stage development as treatment for adult patients with nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC). Nontuberculous mycobacteria (NTM) are organisms that are found in the soil and water that can cause serious lung disease in susceptible individuals for which there are currently limited effective treatments and no approved therapies.

INS1009 an inhaled prodrug formulation of treprostinil is the company’s clinical candidate for pulmonary arterial hypertension (PAH), a chronic life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. The abstracts and poster that will be presented during the ATS conference can be found at, and the titles are as below:

  • The post session entitled: “Preclinical Trials in Pulmonary Hypertension Models: Novel Targets and Delivery”, will be presented on this Sunday, May 17th from 9:30 AM – 4:15 PM;
  • The Abstract Titled “A 14-Day Assessment of the Tolerability and Pharmacokinetics (Pk) with a Nanoparticle Formulation of Hexadecyl-Treprostinil a Long-Acting Pulmonary Vasodilator In Rats”, will be presented by lead author V. Malinin PhD/;
  • The Abstract Titled “Prolonged Pharmacokinetic Profile of a Prodrug Lipid Nanoparticle Formulation of Treprostinil in Dogs”, will be presented by lead author F.G. Leifer PhD.;
  • The Abstract Titled “Effect of a Lipid Nanoparticle Prodrug Formulation of Treprostinil on the Cough Reflex in Guinea Pigs”, will be presented by lead author R.W. Chapman PhD.;
  • The Poster Session entitled “Diagnosis and Management of Nontuberculous Mycobacteria Infections”, will be presented next Wednesday May 20th from 1:30 PM to 3:30 PM;
  • The Abstract Titled “Subgroup Analyses of Baseline Demographics and Efficacy in Patients with Refractory Nontuberculous Mycobacteria (NTM) Lung Infection Treated with Liposomal Amikacin for Inhalation (LAI)”, will be presented by lead author K.L. Winthrop MD.;
  • The Abstract Titled “Efficacy of Liposomal Amikacin for Inhalation (LAI) in Achieving Nontuberculous Mycobacteria (NTM) Culture Negativity in Patients Whose Lung Infection is Refractory to Guideline-Based Therapy”, by lead Author: J.A. Biller MD.;
  • The Abstract Titled “Analysis of Functional Exercise Capacity (Via the Six-Minute Walk Test [6MWT]) and Culture Negativity in Patients with Nontuberculous Mycobacteria (NTM) Lung Infection Refractory to Guideline-Based Therapy Treated with Liposomal Amikacin for Inhalation (LAI)”, will be presented by lead author S.J. Ruoss MD.

Insmed has applied its product design drug development and sustained-release formulation expertise to advance INS1009 with the goal of addressing current limitations of inhaled prostacyclin therapies in the treatment of PAH. INS1009 is expected to be delivered once-daily via inhalation, provide consistent effective drug levels and reduce the acute systemic effects of current treatment options. These new presentations will seek to demonstrate INS1009’s ability to improve patient outcomes and facilitate ease of use and patient compliance with treatment.

A Conversation With Rare Disease Advocates